PTC Therapeutics Inc (PTCT.O): 2Q Takeaways & Model Update

Research evidence excerpt

PTC Therapeutics Inc (PTCT.O): 2Q Takeaways & Model Update

Action |

30 Jul 2026 23:45:30 ET │ 12 pages

PTC Therapeutics Inc (PTCT.O)

2Q Takeaways & Model Update

CITI'S TAKE

Highlights from PTC's 2Q call continue to underscore solid Sephience

growth dynamics in the US and growing momentum ex-US as it becomes a

greater overall contributor into year-end. From here, we see a clear setup to Buy / High Risk

Sephience outperforming trailing 2H estimates (implying 8.5% sequential Short-Term View: Upside, expires 07-SEP-26

growth 3Q/4Q) on expanded patient volume and stable pricing with the

Price (30 Jul 26 16:00) US$75.52bulk of HTAs ongoing (i.e. the start of final EU pricing decisions toward year-

end). On pipeline, we suspect votoplam AA potential maintains an outsized Target price US$108.00

impact on investor sentiment, although our base-case is that approval is Expected share price return 43.0%

phase 3-dependent. That said, we continue to see the votoplam HD

Expected dividend yield 0.0%commercial opportunity and vatiquinone for FA going underappreciated by

current levels on a risk-adjusted basis. Maintain BUY/HR and $108 TP. Expected total return 43.0%

Market Cap US$6,264M

Call commentary underscores solid launch dynamics in the US… — Management

noted continued pull through in each of the three treatment segments (treatment-

naïve, former treatment failures, and therapy switches). Notably, therapy switches

are an increasing proportion of patient mix. Additionally, management notes Price Performance

treatment adoption now at 100% of centers of excellence nationally with steadily

(RIC: PTCT.O, BB: PTCT US)robust renewal rates at >90%.

…with accelerating international contribution into year-end. — Of note,